Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sachs presentation for anyone who hasn't seen it. I am quite impressed. I started an investment here in MRKR future looks bright. I like how they take a different approach to cell therapy and are still able to generate response in cancer patients.
Thanks for the video very nice for MRKR, explains the multi-antigen T-cell therapy approach and why it's better than CAR-T.
This looks ready to pop, did my DD good sized pipeline for risk reduction and solid technology. Also diversified tech as it has 3 different types. I think MRKR is a great long-term hold.
Axovant positive 6-month results in Axo-lenti-pd for parkinson's disease https://www.globenewswire.com/news-release/2019/06/06/1865234/0/en/Axovant-Announces-6-Month-Follow-Up-Data-From-First-Cohort-of-SUNRISE-PD-Phase-2-Trial-of-AXO-Lenti-PD-and-Pipeline-Update.html
Many Presentations coming up for AXGT , I expect new data from most of the studies soon.
https://ih.advfn.com/stock-market/NASDAQ/axovant-sciences-ltd-AXGT/stock-news/80035495/axovant-to-present-at-upcoming-conferences-in-june
tough go around so far, but upcoming catalysts should quickly turn things around. I'm holding AXGT for the long-term.
Dan O'connor ran Advaxis into the ground. Now it looks like he is doing the same to ONCS.
Conference set for tomorrow at 2:00 p.m EST hopefully maybe some results in the morning as well for AXGT
https://ih.advfn.com/stock-market/NASDAQ/axovant-sciences-ltd-AXGT/stock-news/79952124/axovant-to-present-at-2019-rbc-capital-markets-glo
News Axovant dosed first patient GM1 gangliodosis
https://finance.yahoo.com/news/axovant-announces-dosing-first-patient-200500914.html
Management for AXGT is the best. They got Dr. Fraser Wright as the Chief Technology Officer who co-founded Spark Therapeutics. You are crazy.
Axovant 1:8 reverse stock split tomorrow May 8, 2019
https://www.globenewswire.com/news-release/2019/05/07/1818853/0/en/Axovant-Announces-Reverse-Share-Split-Effectiveness.html
IMO it will be followed with a press release as well.
Reversestock split for AXGT should be coming soon within the next week or so in my opinion. It will be much needed.
I will tell this to everyone, I believe the biggest problem for CytoDyn is remaining on the OTC for trading. That's what's killing the company and the stock price. A revere split should be done and it should start to trade on the NASDAQ. Now before you scream at me or ignore me, hear me out.
Right now the price is low at .40 cents per share, so the company to get financing has to keep diluting at this low of a stock price. Then there is the massive float that keeps building up. If the company lists on the NASDAQ and does a reverse split then it could be able to dilute at say $6 per share or $7 per share and get a lot more money for a lot less shares.
Then you have the outstanding shares issue. Either way the company is eventually going to have to do a reverse stock split. That many outstanding shares for a company is not feasible in the long run.
Finally, the only reason why I think CytoyDyn is staying on the OTC is because SEC Filings are not monitored. The OTC doesn't have the same rules for public companies as the NASDAQ has. If there is an issue with financials in OTC, the exchange doesn't care. However, NASDAQ will notify the company. In other words, CytoDyn gets to be more lax when it comes to financials not being known. That's my 2 cents on the matter. I think the CEO means well, but he is hurting the company by not uplisting now.
This is why volume is climbing today
https://www.cbsnews.com/news/the-cruelest-disease-youve-never-heard-of-frontotemporal-dementia-60-minutes-2019-05-02/
News , Next cohort 2 for phase 2 is starting which is mid-dose. Good news
https://ih.advfn.com/stock-market/NASDAQ/axovant-sciences-ltd-AXGT/stock-news/79795007/axovant-announces-dosing-of-first-patient-in-secon
reverse split will be a good thing. Lots of News in May of 2019.
What do you guys think about the upcoming reverse split?
AXGT doing a 1 for 8 reverse stock split
https://seekingalpha.com/pr/17467464-axovant-announces-plan-effect-reverse-share-split
will lower shares down to 22 million.
R&D Day Webcast AXGT
Presentation slides with multiple Doctor speakers working on the studies
https://www.webcaster4.com/Webcast/Page/359/29901
New Seeking Alpha Article on AXGT
https://seekingalpha.com/article/4251397-axovant-reiterating-buy-rating-increased-price-target-7-share
What do you guys expect for R&D day? I hope there is some news in the coming days beforehand.
Roivant 10% or higher owner purchased another 6% of Axovant. Roivant now holds 60% of Axovant shares.
https://www.sec.gov/Archives/edgar/data/1635088/000110465919016010/xslF345X03/a4.xml
Pricing Set at $1.50 time to move up soon after.
http://investors.axovant.com/news-releases/news-release-details/axovant-sciences-announces-pricing-40-million-public-offering
That's all biotechs. Dilution is the selling of common shares which means the float gets a little bit bigger. It doesn't mean your shares get reduced. So if you buy say 3,000 shares, you still have 3,000 shares after the dilution. The thing is that it adds additional shares into the float. Which if it gets too high makes it harder to go up based on market cap.
IMO with the many catalysts coming up this year and pending all positive the stock will be trading north of $10 per share.
You have first dosing of GM1 patient
Dosing of cohort 2 for PHASE 2 SUNRISE-PD study
2 more readouts for GM2 study
2 more readouts for GM1 study
2 more readouts for SUNRISE-PD study
initiation of OPMD phase 1/2 study
all throughout 2019. There are plenty of catalysts to lift the stock higher throughout the year. Of course, that's pending the data turns out strong.
https://www.sec.gov/Archives/edgar/data/1636050/000104746919001193/a2238033z424b5.htm
But read the Prospectus, Roivant is going to likely purchase shares in the offering.
It's a public offering , no price yet announced.
http://investors.axovant.com/news-releases/news-release-details/axovant-sciences-announces-public-offering-common-shares-0
The problem right now is that there might be the old stigma of shorts from the old AXON ticker. I say give it time for AXGT to take off.
There are still multiple catalysts in 2019.
You have 2 more interim readouts for GM2 in 2019
2 more interim readouts for PD in 2019
Trial initiation for GM1 study expected in coming weeks/months
possibly 1 t 2 interim updates in 2019 for GM1 study.
Initiation of the OPMD silence and replace program from Benitec biopharma expected 2nd half of 2019
Then any other potential cash infusion news as well.
It will take some time but I think it can get there.
New Axovant presentation posted, took down old one because link was gone. Here is new one to start research
http://investors.axovant.com/static-files/02c997e8-92d8-443f-9f7e-91e60e364470
Thanks I decided to make a board for AXGT heavily invested with largest position. I see a good future with this biotech. Tech looks promising in early stages and Fraser Wright current CTO of AXGT used to be CTO and co-founder of Spark Therapeutics. We are in good hands.
Positive results in the 1st child for Tay-Sachs disease good for the patients and for AXGT investors
https://seekingalpha.com/pr/17439127-axovant-announces-clinical-update-first-tay-sachs-disease-patient-dosed-axo-aav-gm2-gene
super positive results in 2 PD patients in cohort 1 https://seekingalpha.com/pr/17439129-axovant-reports-positive-interim-results-first-cohort-sunrise-pd-phase-2-trial-axo-lenti-pd
Axovant Sciences is going to present on Monday March 11, 2091 at 12:00 p.m. est time at COWEN AND COMPANY 39TH ANNUAL HEALTH CARE CONFERENCE
http://investors.axovant.com/news-releases/news-release-details/axovant-present-cowen-and-company-39th-annual-health-care
Webcast here for those interested
http://wsw.com/webcast/cowen52/register.aspx?conf=cowen52&page=axon&url=http://wsw.com/webcast/cowen52/axon/index.aspx
Axovant Sciences Investor Presentation Get started Here on initial research for pipeline programs January 2019.
http://investors.axovant.com/static-files/ee5f36e9-dab5-4c72-b0ea-2767578f73a8
Look at CEO's closing comments on CYDY conference call. He states TNBC dosing to begin in next few weeks with data possibly by Q3 2019.
He didn't say dilution. He stated that he had rejected a dilution that was to be offered for .30 cents I think you misunderstood what the CEO said.
People you have it all wrong.
He said best case scenario Q2 and worst case scenario Q3 2019.